Search Results for keywords:"Drug Enforcement Administration"

The Drug Enforcement Administration (DEA) issued an order to revoke the registration of Dr. Ajumobi Agu in Nevada due to violations of the Controlled Substances Act (CSA). Dr. Agu continued prescribing controlled substances even after his state medical and controlled substances licenses were suspended. The DEA concluded that his actions are inconsistent with the public interest and deemed him untrustworthy to handle such substances. As such, Dr. Agu will be unable to apply to renew or modify his DEA registration, effective May 16, 2025.

Organix, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered producer of certain controlled substances, specifically synthetic versions of Marihuana and Tetrahydrocannabinol. The notice invites comments or objections from existing registered manufacturers and applicants by March 15, 2021. Requests for a hearing on the application must also be submitted by this date. Written feedback should be directed to the DEA in Springfield, Virginia.

Purisys, LLC has applied to become a registered bulk manufacturer of certain controlled substances, as announced by the Drug Enforcement Administration (DEA) under the Justice Department. The company intends to produce these substances for use as active pharmaceutical ingredients and analytical reference standards, and to support clinical trials. People or companies who are already registered bulk manufacturers or applicants of these substances may submit comments or request a hearing on the application by April 21, 2025. Comments must be submitted electronically via the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) is revoking the registration of Dr. Harvey Leslie, which allowed him to handle controlled substances. This is because his medical license in Georgia has been revoked, and he can no longer practice medicine or legally handle controlled substances there. Since having a valid state license is necessary to maintain DEA registration for handling controlled substances, Dr. Leslie's registration is being revoked, effective April 28, 2025. The decision was signed by the Acting Administrator, Derek Maltz, on March 20, 2025.

The Drug Enforcement Administration (DEA), part of the Department of Justice, is planning to submit an information collection request to the Office of Management and Budget (OMB) for approval. This collection involves the Leadership Engagement Survey, which is administered annually to federal government employees, contractors, and task force officers working at the DEA. The survey is voluntary and takes about 20 minutes to complete, with an expected response count of around 5,000 people. The DEA is seeking authorization to conduct this survey for three years, which will not incur additional costs since it operates on an existing internal platform.

Noramco has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances, including Poppy Straw Concentrate and an intermediate form of Tapentadol. They plan to use these substances to manufacture other drugs for their customers. As part of their application, they also intend to import synthetic cannabidiol and synthetic Tetrahydrocannabinol, while noting that they will not import finished drugs for commercial sale. The public can submit comments or request a hearing on this application by January 6, 2025.

Scottsdale Research Institute has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. This registration is intended to support the production of these substances for clinical trials and research purposes. The public can submit comments or objections electronically through the Federal eRulemaking Portal by April 21, 2025. The DEA requires comments to be submitted online and will provide a tracking number to confirm submission.

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import these substances solely for clinical trials. Other types of uses or commercial sales are not allowed under this registration. Interested parties can submit comments or objections electronically by April 16, 2025, and can also request a hearing on the application by the same date.

Purisys, LLC has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of various controlled substances, including different forms of opium and marihuana extracts, for manufacturing purposes. The company aims to import these substances to create active pharmaceuticals and other controlled substances for its customers. Any comments or objections to this application must be submitted electronically by March 17, 2025. The approval for these imports will only be granted if the business activities align with legal requirements, and the import of finished dosage forms for commercial sale is not authorized.

Sterling Pharma USA LLC has applied to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of controlled substances. This application, filed on February 11, 2025, aims to support the company's internal research and provide substances for pre-clinical trial studies. The public can comment or object to this registration until May 16, 2025, through the Federal eRulemaking Portal.